Serum lysozyme in inflammatory gastric and enteric diseases and in functional dyspepsia.
Serum lysozyme was reevaluated in inflammatory bowel disease and other gastrointestinal disorders. A total of 109 patients were divided into six groups: ulcerative colitis (28), Crohn's disease (9), simple atrophic gastritis (16), atrophic gastritis and pernicious anemia (23), functional dyspepsia (17), and controls (16). Elevated levels of lysozyme, compared with control levels, were found not only in ulcerative colitis and Crohn's disease but also in atrophic gastritis with or without pernicious anemia and in functional dyspepsia. The elevation of lysozyme, since it results from the product of granulocytes and macrophages present in increased amounts in the mucosa of inflammatory bowel diseases, is easily explained. The cellular infiltration in atrophic gastritis may also explain the elevated lysozyme levels. The higher lysozyme levels in some patients with functional dyspepsia could possibly reflect an underlying latent inflammatory process.
D000328:Adult; D000368:Aged; D000752:Anemia, Pernicious / Q000201:enzymology; D003093:Colitis, Ulcerative / Q000201:enzymology*; D003424:Crohn Disease / Q000201:enzymology*; D004415:Dyspepsia / Q000201:enzymology*; D005260:Female; D005756:Gastritis / Q000201:enzymology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009113:Muramidase / Q000097:blood*
D009113:Muramidase